Key Events This Week
2 Mar: Stock opens week at Rs.144.30, down 3.77%
4 Mar: Hits 52-week low at Rs.137.95 amid continued downtrend
5 Mar: Downgraded to Strong Sell by MarketsMOJO
6 Mar: Week closes at Rs.144.00, down 0.31% on day
2 March 2026: Week Begins with Sharp Decline
Nath Bio-Genes opened the week at Rs.144.30 on 2 March 2026, down 3.77% from the previous close of Rs.149.95. This decline outpaced the Sensex’s 1.41% fall to 35,812.02, signalling early weakness in the stock amid broader market volatility. The volume of 2,734 shares indicated moderate trading interest as investors reacted to ongoing concerns about the company’s fundamentals.
4 March 2026: Stock Hits 52-Week Low Amid Continued Downtrend
On 4 March, Nath Bio-Genes’ stock price fell further by 2.91% to Rs.140.10, reaching a fresh 52-week low intraday at Rs.137.95. This marked a significant milestone in the stock’s persistent downtrend, which has seen it decline from a 52-week high of Rs.238.00. The drop occurred despite the Agri-Seeds sector’s own decline of 2.86%, with Nath Bio-Genes underperforming both its sector and the Sensex, which fell 1.92% to 35,125.64.
The stock’s technical position remained weak, trading below all key moving averages, signalling sustained bearish momentum. Financially, the company reported a loss before tax of Rs.1.95 crore for the quarter ended December 2025, a 158.91% decline, and a net loss of Rs.0.15 crore, down 105.5%. Cash reserves were low at Rs.0.74 crore, raising concerns about liquidity and operational flexibility.
Fresh entry alert! This Small Cap from Electronics & Appliances sector is already turning heads in our Top 1% club. Get ahead of the market now!
- - New Top 1% entry
- - Market attention building
- - Early positioning opportunity
5 March 2026: Downgrade to Strong Sell Reflects Weak Fundamentals and Bearish Technicals
MarketsMOJO downgraded Nath Bio-Genes from a ‘Sell’ to a ‘Strong Sell’ rating on 5 March 2026, citing deteriorating fundamentals and technical indicators. The company’s Mojo Score dropped to 26.0, signalling heightened caution. The downgrade followed a series of disappointing financial results, including a 158.91% decline in profit before tax and a 105.5% fall in net profit after tax.
Technical analysis revealed bearish signals across multiple indicators. The monthly MACD was bearish, Bollinger Bands suggested increased downward volatility, and daily moving averages confirmed a negative trend. Institutional investors reduced their holdings by 0.76% in the previous quarter, now holding only 0.32% of shares, reflecting declining confidence.
Despite an attractive valuation with an Enterprise Value to Capital Employed ratio of 0.5 and a PEG ratio of 1.4, the stock’s price continued to decline, closing at Rs.143.00 on 5 March, up 2.07% on the day but still well below recent highs.
6 March 2026: Week Ends with Minor Recovery Amid Market Volatility
The stock closed the week at Rs.144.00 on 6 March 2026, up 0.70% from the previous day’s close. This modest gain came despite the Sensex falling 0.98% to 35,232.05, indicating a slight outperformance on the day. However, the weekly decline of 3.97% for Nath Bio-Genes exceeded the Sensex’s 3.00% fall, underscoring the stock’s relative weakness.
Trading volume remained subdued at 308 shares, reflecting limited investor enthusiasm. The stock remains near its 52-week low, with technical and fundamental headwinds continuing to weigh on sentiment.
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-03-02 | Rs.144.30 | -3.77% | 35,812.02 | -1.41% |
| 2026-03-04 | Rs.140.10 | -2.91% | 35,125.64 | -1.92% |
| 2026-03-05 | Rs.143.00 | +2.07% | 35,579.03 | +1.29% |
| 2026-03-06 | Rs.144.00 | +0.70% | 35,232.05 | -0.98% |
Key Takeaways from the Week
Persistent Downtrend: Nath Bio-Genes’ stock continued its downward trajectory, hitting a 52-week low of Rs.137.95 on 4 March, reflecting ongoing challenges in regaining investor confidence.
Deteriorating Fundamentals: The company reported significant losses in profit before tax and net profit, alongside low cash reserves of Rs.0.74 crore, highlighting financial stress and limited liquidity.
Technical Weakness: Multiple bearish technical indicators, including moving averages and Bollinger Bands, signalled sustained negative momentum, culminating in a downgrade to a strong sell rating.
Institutional Disengagement: A decline in institutional ownership to 0.32% suggests waning confidence from sophisticated investors, potentially increasing selling pressure.
Nath Bio-Genes (India) Ltd or something better? Our SwitchER feature analyzes this micro-cap stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Conclusion: A Challenging Week for Nath Bio-Genes
The week ending 6 March 2026 was marked by continued weakness for Nath Bio-Genes (India) Ltd, with the stock falling 3.97% and touching a 52-week low. The downgrade to a strong sell rating by MarketsMOJO reflected the company’s deteriorating fundamentals, bearish technical outlook, and declining institutional interest. Despite an attractive valuation on some metrics, the stock’s persistent underperformance relative to the Sensex and sector peers underscores the risks facing investors. Until there is clear evidence of operational improvement and technical recovery, the stock remains under pressure in a challenging market environment.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
